MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Exact Sciences Corporation Total Assets 2011-2026 | EXAS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.86 B | 5.93 B | 6.47 B | 6.23 B | 6.68 B | 4.93 B | 3.51 B | 1.52 B | 599 M | 377 M | 364 M | 312 M | 147 M | 112 M | 97 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.68 B | 97 M | 2.88 B |
Quarterly Total Assets Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 B | 5.8 B | 5.71 B | 5.93 B | 6.75 B | 6.67 B | 6.38 B | 6.47 B | 6.42 B | 6.36 B | 6.3 B | 6.23 B | 6.31 B | - | 6.49 B | 6.68 B | 6.65 B | 6.72 B | 6.73 B | 4.93 B | 4.93 B | 4.93 B | 4.93 B | 3.51 B | 3.51 B | 3.51 B | 3.51 B | 1.52 B | 1.52 B | 1.52 B | 1.52 B | 599 M | 599 M | 599 M | 599 M | 377 M | 377 M | 377 M | 377 M | 364 M | 364 M | 364 M | 364 M | 313 M | 313 M | 313 M | 313 M | 147 M | 147 M | 147 M | 147 M | 112 M | 112 M | 112 M | 112 M | 97 M | 97 M | 97 M | 97 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.75 B | 97 M | 2.8 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 0.73 | -1.86 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 23.87 | -0.13 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
245 M | $ 104.95 | -1.72 % | $ 4.14 B | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
6.34 B | $ 73.08 | 1.11 % | $ 28.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 11.75 | 2.8 % | $ 333 M | Israel |
 |
CareDx, Inc
CDNA
|
467 M | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
6.3 B | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 74.31 | 1.54 % | $ 5.14 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 99.61 | 1.22 % | $ 8.22 B | Irlanda |
 |
Interpace Biosciences
IDXG
|
14.8 M | $ 1.85 | 2.78 % | $ 8.12 M | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
3.29 B | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 166.19 | -1.87 % | $ 28.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 31.19 | 0.73 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
97.2 M | $ 13.26 | 4.0 % | $ 1.72 B | USA |
 |
Quidel Corporation
QDEL
|
1.87 B | $ 22.47 | -4.85 % | $ 947 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
811 M | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
122 M | $ 13.65 | 9.64 % | $ 335 M | USA |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 378.44 | 0.14 % | $ 28.4 B |  Schweiz |